1. What Is the HIV Treatment Market?
The HIV Treatment Market covers the antiretroviral therapy combinations used to suppress the HIV-1 and HIV-2 replication to below 50 copies per mL in the more than 39 million people globally living with HIV. The approved drug classes include the nucleoside reverse transcriptase inhibitors, the non-nucleoside reverse transcriptase inhibitors, the integrase strand transfer inhibitors, and the protease inhibitors. HIV ART has evolved to the single-tablet regimens with the bictegravir-tenofovir alafenamide-emtricitabine and the dolutegravir-abacavir-lamivudine. The long-acting injectable cabotegravir-rilpivirine provides the injectable option. The HIV treatment market is advancing with the lenacapavir twice-yearly subcutaneous injection for the treatment-experienced multidrug-resistant HIV. The PURPOSE 1 trial demonstrated the lenacapavir as the pre-exposure prophylaxis achieving 100 percent HIV prevention in cisgender women.
2. HIV Treatment Market Size & Forecast
3. Emerging Technologies
- Biktarvy bictegravir-tenofovir alafenamide-emtricitabine single-tablet once-daily integrase inhibitor-based regimen Phase III demonstrated the 92 to 95 percent viral suppression below 50 copies at 48 weeks. The high barrier to resistance comes from the bictegravir and the renal and bone safety advantage of TAF over TDF. The regimen is the most prescribed HIV regimen globally.
- Long-acting injectable cabotegravir plus rilpivirine Cabenuva ATLAS and FLAIR Phase III demonstrated the 92 to 93 percent viral suppression at 48 weeks. The ATLAS-2M trial confirmed the every-2-month injection schedule as non-inferior to monthly. The regimen provides the monthly or bimonthly clinic-based injection alternative to the daily oral pill.
- Lenacapavir CAPELLA Phase II/III for the multidrug-resistant HIV demonstrated 72 percent viral suppression at 52 weeks with the twice-yearly subcutaneous injection. The capsid inhibitor targets the novel HIV capsid protein. The drug provides the long-acting option for the treatment-experienced patient with the limited treatment options.
- PURPOSE 1 lenacapavir PrEP trial in cisgender African women and adolescent girls demonstrated 100 percent HIV prevention efficacy versus placebo from the twice-yearly injection. The trial established the injectable PrEP that overcomes the oral tenofovir daily adherence challenge. The PURPOSE 2 trial extends the evaluation to the broader population.
Similar technologies are also transforming adjacent markets. Learn more in our Infectious Disease Drug Market.
4. Key Market Opportunity
A major opportunity in the HIV Treatment market is long-acting injectable and lenacapavir adoption expanding beyond oral HIV therapy, where the convenience of monthly, bi-monthly, and twice-yearly injections drives prescribing transitions from daily oral therapy. ViiV Healthcare and Gilead Sciences capture this long-acting HIV therapy opportunity. A separate growth lever stems from broadly neutralising antibody development as next-generation HIV therapy and prevention. As long-acting injectable adoption proceeds and bNAb development advances, the addressable opportunity is evolving from daily oral HIV management toward long-acting and bNAb-based HIV therapy.
5. Top Companies in the HIV Treatment Market
The following organisations hold leading positions in the HIV Treatment Market. The full report provides revenue share, SWOT analysis, and competitive benchmarking for each player.
- Gilead Sciences
- GSK
- Johnson and Johnson
- Merck
- Theratechnologies
- Hetero Labs
- Aurobindo Pharma
- Cipla
- Sun Pharma
- Dr. Reddy's
- Lupin
- Viatris
- Sandoz
- Bristol-Myers Squibb
- Wockhardt
6. Market Segmentation
The HIV Treatment Market is analysed across 4 segmentation dimensions. Revenue data, growth rates, and competitive intensity by sub-segment are available in the full report.
| Segmentation | Sub-Segments |
|---|---|
| By Drug Class | INSTINNRTIPINRTILong-Acting InjectablebNAb |
| By Drug | BictegravirDolutegravirCabotegravirRilpivirineLenacapavir |
| By Setting | Treatment-NaiveTreatment-ExperiencedPrevention |
| By Geography | North AmericaEuropeAsia PacificLatin AmericaMiddle East and Africa |
7. Key Market Trends (2026–2034)
Three major forces are shaping the HIV Treatment Market trajectory over the forecast period:
Biktarvy Bictegravir-TAF-FTC 92 to 95 Percent Viral Suppression With High Bictegravir Resistance Barrier and TAF Renal and Bone Safety Has Made the Single-Tablet Once-Daily Integrase Inhibitor Regimen the Most Prescribed HIV Treatment Globally.ViiV Healthcare's cabotegravir plus rilpivirine Cabenuva demonstrated non-inferior viral suppression at 48 weeks and 96 weeks compared with daily oral regimens in both treatment-naive and treatment-experienced switch populations, establishing that injection-based ART achieves equivalent long-term virological outcomes to the oral regimens that have been the standard since 1996. The 2-year ATLAS extension data showing 94% viral suppression with monthly CAB+RPV versus 93% with oral regimens demonstrates durability of the long-acting injection effect that was the primary uncertainty following the initial 48-week non-inferiority demonstration. A programmatic challenge for long-acting ART is the consequence of missed injections, where a 7-day grace period for monthly dosing requires patient and provider education about the risk of rilpivirine resistance from subtherapeutic drug levels that develop if the injection interval is substantially extended beyond the permitted window.
Cabenuva Monthly or Bimonthly Cabotegravir Plus Rilpivirine Injectable ATLAS and FLAIR 92 to 93 Percent Viral Suppression Has Provided the Clinic-Based Injection Alternative That Eliminates the Daily Oral Adherence Burden for the Virologically Stable HIV Patient.Gilead Sciences's lenacapavir Sunlenca demonstrated 72.6% viral suppression at 52 weeks in heavily treatment-experienced patients with resistance to multiple antiretroviral classes in CAPELLA, a clinically extraordinary result in a population where prior rescue regimens achieved under 30% sustained viral suppression. The capsid inhibitor mechanism blocks multiple stages of HIV replication including nuclear import, intracellular transport, and particle assembly through binding the hexameric capsid protein at a conserved interface that differs from all prior ART targets, creating a class with no cross-resistance to existing resistance mutations. The once-every-26-week subcutaneous injection of lenacapavir from fully soluble formulation creates the longest dosing interval of any approved ART agent, and the class's combination with bictegravir or islatravir in treatment-naive and experienced populations is being investigated to use the capsid's distinct mechanism in earlier treatment lines.
Lenacapavir PURPOSE 1 Twice-Yearly Subcutaneous Injection 100 Percent HIV Prevention in Cisgender African Women Has Established the Capsid Inhibitor Injectable PrEP That Long-Acting Dosing Eliminates the Daily Oral Adherence Challenge That Population-Level PrEP Scale-Up Requires.ViiV Healthcare's dolutegravir plus lamivudine GEMINI and SALSA trials demonstrated non-inferior viral suppression at 48 and 148 weeks in treatment-naive patients versus three-drug tenofovir-containing regimens, establishing a two-drug option that reduces the cumulative nucleoside analogue exposure associated with long-term renal and bone toxicity. The dual nucleoside-free approach eliminates the tenofovir backbone that had been considered essential for maintaining the high genetic barrier to integrase resistance through pharmacological complementarity, and the TANGO switch trial confirmed similar virological maintenance when stable patients on three-drug therapy switched to the two-drug combination. The two-drug regimen commercial positioning by ViiV targets the large population of patients with established HIV on TDF-based regimens who have renal function concerns or bone mineral density loss that motivates reducing nucleoside backbone exposure while maintaining virological suppression.
For related market intelligence, see the Antiviral Drug Market.
8. Segmental Analysis
By drug class, the integrase inhibitor segment dominated the HIV Treatment Market in 2025, as Gilead Sciences's Biktarvy and dolutegravir-based regimens anchored first-line therapy in both high-income and resource-limited settings, generating the dominant share of antiretroviral revenue worldwide.
By route, the long-acting injectable segment is projected to register the highest growth rate through 2034, as ViiV Healthcare's Cabenuva and Gilead Sciences's injectable lenacapavir shift treatment from daily oral pills to monthly and biannual dosing in adherence-challenged populations.
9. Regional Analysis
Regional demand patterns across the HIV Treatment Market reflect differences in regulation, technological maturity, and capital investment.
Largest Market Share
North America dominated the HIV Treatment Market in 2025, accounting for approximately 43% of global revenue, due to US premium pricing for Biktarvy, long-acting injectable Cabenuva, and lenacapavir and the large HIV-treated patient population with payer coverage. Moreover, long-acting injectable adoption is most advanced in the US. In addition, lenacapavir treatment and prevention use is growing. Regional dominance is attributed to this combination of pricing environment and long-acting HIV adoption.
Highest CAGR Region
Asia Pacific is projected to register the highest CAGR in the HIV Treatment Market through 2034, driven by the large HIV patient population in China, India, and Southeast Asia and expanding access to generic antiretrovirals and emerging long-acting injectables. The region is also witnessing dolutegravir-based regimen adoption growing. Moreover, HIV treatment access programmes are expanding. The combination of these demand drivers and patient scale positions Asia Pacific for sustained growth outperformance through 2034.
10. Full Report with Exclusive Insights
The complete published market report includes an in-depth analysis of market dynamics, industry trends, competitive landscape, regional outlook, and future growth opportunities. The study provides detailed market sizing and forecasts across key segments and geographies, along with comprehensive insights into drivers, restraints, opportunities, challenges, technological advancements, regulatory landscape, and evolving consumer and industry trends. The report also features company profiles, strategic developments, market share analysis, and actionable recommendations to support informed business decision-making. Additionally, the syndicated report package typically includes forecast datasets, charts and figures, research methodology, and analyst support for strategic interpretation and planning.
Advanced Strategic & Custom Intelligence
In addition to the standard syndicated report package, TrendX Insights can provide the following advanced strategic analyses and customized intelligence solutions for any market:
Standard Report Coverage
- • Competitor Analysis
- • Country Trade Analysis
- • Import & Export Analysis
- • Porter’s Five Forces Analysis
- • SWOT Analysis by Companies
- • TrendX Insights Quadrant Positioning
- • Pricing Analysis
- • Detailed Macro-Economic Indicators Assessment
- • List of Raw Material Suppliers
- • Regulatory Framework Assessment
- • Supply Chain Resilience Mapping
- • Value Chain Analysis
- • Technology adoption trends and innovation tracking
- • Custom company profiling and benchmarking
Exclusive Sections With Additional Cost
- • Agentic AI Readiness Score
- • TAM, SAM, and SOM Analysis
- • AI Act & Privacy Compliance Audit
- • Channel Partner Ecosystem Mapping
- • China + 1 Strategy Analysis
- • Circular Economy Opportunities Assessment
- • Competitor Benchmarking KPI Analysis
- • Country Trade Analysis
- • Country-level opportunity mapping
- • Digital Maturity Matrix
- • Ecosystem Interdependency Mapping
- • ESG & Decarbonization Roadmap
- • Geopolitical Friction Scorecard
- • Geopolitical Risk Assessment
- • Humanoid Workforce Impact Analysis
- • Investment Heatmap
- • List of Distributors and Channel Partners
- • List of Raw Material Suppliers
- • Market Entry Strategy Assessment
- • Mergers & Acquisitions (M&A) Analysis
- • Patent & Intellectual Property (IP) Analysis
- • Pilot Project Analysis
- • Potential High-Growth Region/Country Investment Assessment
- • Product Comparison Analysis
- • Product Revenue Analysis
- • R&D Investment Analysis in Emerging Technologies
- • Raw Material Scarcity Forecast
Note: For highly customized requirements, deeper strategic assessments, company-specific intelligence, or tailored consulting support, please contact TrendX Insights.
Full Report with Exclusive Insights
Available to clients on request
Explore Our Published Reports Library
This page covers market-level data estimates. For comprehensive published research reports including full methodology, primary data, and detailed company profiles, browse the TrendX Insights Published Reports Library.
Visit Published Reports Library ›11. Related Market Reports
Frequently Asked Questions
The HIV Treatment Market was valued at USD 32.86 Bn in 2025 and is projected to reach USD 50.11 Bn by 2034, growing at a CAGR of 4.8% over the 2026–2034 forecast period.
The HIV Treatment Market is projected to grow at a CAGR of 4.8% from 2026 to 2034.
North America dominated the HIV Treatment Market in 2025, accounting for approximately 43% of global revenue, due to US premium pricing for Biktarvy, long-acting injectable Cabenuva, and lenacapavir and the large HIV-treated patient population with payer coverage.
The leading companies in the HIV Treatment Market include Gilead Sciences, GSK, Johnson and Johnson, Merck, Theratechnologies, Hetero Labs, Aurobindo Pharma, Cipla, Sun Pharma, Dr. Reddy's, Lupin, Viatris, Sandoz, Bristol-Myers Squibb, Wockhardt.
Biktarvy bictegravir-taf-ftc 92 to 95 percent viral suppression with high bictegravir resistance barrier and taf renal and bone safety has made the single-tablet once-daily integrase inhibitor regimen the most prescribed hiv treatment globally.
By drug class, the integrase inhibitor segment dominated the HIV Treatment Market in 2025, as Gilead Sciences's Biktarvy and dolutegravir-based regimens anchored first-line therapy in both high-income and resource-limited settings, generating the dominant share of antiretroviral revenue worldwide.
How to Order
Purchasing a TrendX Insights report is straightforward. Our process is designed to be transparent and risk-free for buyers, with a 20% upfront model and full delivery before the balance payment.
This is the price of the syndicated report. Any custom inclusions beyond the Table of Contents will be scoped and priced separately. For the full list of what is covered in the syndicated report, refer to the Table of Contents tab.
A curated, condensed version of this report for students, researchers, and academic institutions. Ideal for thesis work, dissertations, and academic projects. Delivered as PDF to your institutional email.
Valid student ID or institutional email required. For educational and non-commercial use only.